A long-term follow-up of botulinum toxin A in cervical dystonia
Authors: Mohammadi, B.1; Buhr, N.1; Bigalke, H.2; Krampfl, K.1; Dengler, R.1; Kollewe, K.1
Source: Neurological Research, Volume 31, Number 5, June 2009 , pp. 463-466(4)
Publisher: Maney Publishing
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Objective: Cervical dystonia (CD) is the most common form of adult-onset focal dystonia, and botulinum toxin A (BoNT-A) has become the first-line treatment for this condition.Methods: In this work, we present data of 207 CD patients treated with BoNT-A for 6.7 ± 3.5 years. One hundred and sixty-three patients were treated with Dysport (mean dose, 389 ± 144 U) and 44 with Botox (mean dose, 145 ± 44 U).Results: The mean clinical benefit, based on a 0-3 scale (0=no effect, 1=slight, 2=moderate and 3=marked improvement) was similar for Dysport (2.5 ± 0.3) and Botox (2.2 ± 0.4). Adverse events were mild and similar for both products. Fewer than 2% of the patients developed neutralizing antibodies.Discussion: These data confirm the efficacy and safety of BoNT-A treatment in CD over an extended period of up to 14 years.Keywords: BOTULINUM TOXIN; CERVICAL DYSTONIA; LONG-TERM FOLLOW-UP
Document Type: Research article
DOI: 10.1179/174313209X405137
Affiliations: 1: Department of Neurology and Clinical Neurophysiology, Hannover Medical School, Hannover, Germany 2: Department of Toxicology, Hannover Medical School, Hannover, Germany
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help